Why Avidity Biosciences Zoomed to a 12% Gain This Week

The company's most promising pipeline program can continue unabated. Clinical-stage biotech Avidity Biosciences (RNA 0.53%) had some good news to report toward the end of this week, and investors rewarded it by piling into the company's stock. By the close of trading Friday, said equity had risen almost 12% in value across the week, according to data compiled by S&P Global Market Intelligence. Partial clinical hold released On Thursday, Avidity announced that the U.S. Food and Drug Administration (FDA) has ...